02 MOU with NEURMEDY for Parkinson’s disease diagnosis & treatment
04 Selected by MOHW(Non-clinical developement of an insulin receptor-targeted anti-diabetic drug)


01 Selected by KDDF (Preclinical development of diabetes treatment)
05 MOU with EONE medical foundation for aptamer technology-based diagnosis


04~07 Invested by VC, including Korea investment partners ($9.8 B)
05 ISO13485 approval for the manufacturing facility (AptoDetectTM-Lung)
06 Selected as an innovation R&D project by SMBA (Development of rapid Multivariate Index Diagnostics technology for diabetic retinopathy using aptamer)
08 CE approval for Lung cancer diagnostic kit (AptoDetectTM-Lung)
09 MTA with Novo Nordisk for evaluation of new diabetes allosteric substance
11 Partnership with BGT in China (AptoDetectTM-Lung)
MOU with Hanlim pharmaceutical company for development of macular degeneration treatment


09 Manufacturing class III medical device approval from ministry of food and drug safety (AptoDetectTM-Lung)


01 GMP certificate for in vitro diagnostic class III medical device (Ministry of Food and Drug Safety)
05~06 VC investment, including Korea investment partners ($7.1 B)
07 Corp Research Institute relocation (Seoul University Bundang Hospita Healthcare Innovation Park)
Approved as InnoBiz (SMBA)
12 Selected by KDDF (Ministry of Food and Drug Safety)


06 Selected as a start-up growth project by SMBA (Norovirus rapid detection method)
07 Licensing product for medical device manufacturing and lung cancer IVD export (KFDA)


03 Project from Ministry of Health and Welfare (Influenza virus diagnosis)
06 Secured 6 oversea partners for research reagent business (USA, Europe, Japan, etc.)
09 Opening of diagnostic laboratory in Seoul Asan Hospital, clinical development for lung cancer IVD Kit
10 MOU with BIC in China (Developed local business partners in China)


06 Selected as a start-up growth project by SMBA (Cancer and vascular endothelial cell separation kit)
09 Research collaboration with SKT (Development of lung cancer IVD Kit for Chinese market)
10 MOU with SKT for commercialization of early lung cancer diagnostic kit


03 Invested by POSCO ($2M)


04 Aptamer sciences Inc. was founded
05 Approved as venture company
06 Licensing agreement for the aptamer technology (POSTECH)
Invested by POSTECH Industry-Academic Cooperation Group
Development partnership with Novartis for the discovery of therapeutic aptamer
07 Approved as Corp Research Institute
11 Selected as a start-up growth project by SMBA (Pull-down assay kit development)